Financing
Noncontrolling interest transactions and other
Regeneron Pharmaceuticals Noncontrolling interest transactions and other increased by 100.0% to $0.00 in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 100.0%, from -$10.30M to $0.00.
Analysis
StatementCash Flow Statement
SectionFinancing
First reportedQ1 2022
Last reportedQ1 2026Apr 29, 2026
Metric ID:
lin_noncontrolling_interest_transactions_and_otherHistorical Data
11 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$33.40M | $0.00 | -$10.30M | $0.00 |
| QoQ Change | — | — | — | — | — | — | — | — | +100.0% | — | +100.0% |
| YoY Change | — | — | — | — | — | — | — | — | — | — | +100.0% |
Range-$33.40M – $0.00
Avg YoY Growth+100.0%
Median YoY Growth+100.0%
Noncontrolling interest transactions and other at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's noncontrolling interest transactions and other?
- Regeneron Pharmaceuticals (REGN) reported noncontrolling interest transactions and other of $0.00 in Q1 2026.
- How has Regeneron Pharmaceuticals's noncontrolling interest transactions and other changed year-over-year?
- Regeneron Pharmaceuticals's noncontrolling interest transactions and other increased by 100.0% year-over-year, from -$10.30M to $0.00.